With TScan Therapeutics Up 12%, Insider Buyers Count Their Returns [Yahoo! Finance]
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: Yahoo! Finance
The company's market value increased by US$27m as a result of the stock's 12% gain over the same period. Put another way, the original US$108.8k acquisition is now worth US$227.3k. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. Check out our latest analysis for TScan Therapeutics The Last 12 Months Of Insider Transactions At TScan Therapeutics Over the last year, we can see that the biggest insider purchase was by Chairman of the Board Timothy Barberich for US$100k worth of shares, at about US$2.63 per share. We do like to see buying, but this purchase was made at well below the current price of US$5.18. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive. While TScan Therapeutics insiders bought shares during the last year, they didn't sell. The chart below shows insider transactio
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and ExpositionGlobeNewswire
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market OpportunitiesGlobeNewswire
- TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.MarketBeat
- TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
TCRX
Earnings
- 8/12/25 - In-Line
TCRX
Sec Filings
- 12/23/25 - Form 4
- 11/26/25 - Form 8-K
- 11/12/25 - Form 10-Q
- TCRX's page on the SEC website